Smart targeting of prosthetic joint infections.
BioVinc is a leader in the development of novel bone disease selective therapeutics and diagnostics.
The Global Impact of PJI
Difficult to Treat Bone Infections
Prosthetic Joint Infections (PJI) represent a critical unmet medical need, contributing to a high rate of amputations and significant patient mortality.
Our lead OsteoFloxacin™ offers a cure for PJI and could ultimately become the gold standard for treating all bone infections.
Thus, OsteoFloxacin™ is an innovative drug and it is eligible for orphan drug status for its first indication with the FDA.
Safeguard Lives and Limbs with OsteoFloxacin™ SmartTargeting
Safety
OsteoFloxacin™ limits soft tissue exposure, reducing typical antibiotic side effects.
Efficacy
OsteoFloxacin™ offers the potential for a true cure.
Derisked
OsteoFloxacin™ incorporates a robust therapeutic approach with a trusted history of clinical use.
Pioneering Experts in Research, Medicine, and Development
Meet the team of innovators tackling prosthetic joint infection treatment and delivering pre-clinical and IND-phase assets.
News
Keep up-to-date with the latest news about BioVinc for media updates for investors, scientists and patients.
Keep up-to-date with the latest news about BioVinc for media updates for investors, scientists and patients.
Revolutionizing the Treatment of PJI
Contact us for intellectual property updates, events and more.